Brain · 2024 · 10 citations · 31 references
MedicineNeurosciencePharmacologyMolecular NeuroscienceNeuropharmacologyPsychopharmacologyAddictionAddiction NeurobiologyAlcohol DependenceAlcohol PharmacologyDopaminergic PharmacologySubstance IntoxicationAlcohol Self-administrationAlcohol Use Disorder TreatmentsDopaminergic NeuronsDopaminergic System EffectsNeuroadaptive Responses To AlcoholPrefrontal Cortex PhysiologySerotonergic System EffectsVentral Tegmental Area Circuits
The use of psilocybin to treat alcohol use disorder is very promising, but its mechanisms of action remain poorly understood. We combined behavioural, pharmacological and gene expression analyses to decipher the mechanisms of action of psilocybin, for the first time, when injected into the brain. Male Long Evans rats underwent chronic operant ethanol self-administration before testing the effect of intraperitoneal psilocybin or directly within the nucleus accumbens core or the ventral tegmental area. Transcripts from the dopaminergic system were quantified in the nucleus accumbens and prefrontal cortex. Psilocybin significantly reduced (by 50%) ethanol self-administration when injected 4 h before the session either intraperitoneally (1 mg/kg) or directly within the left nucleus accumbens (0.15 μg) but not the right nucleus accumbens or the left ventral tegmental area. The effect of intraperitoneal injection of psilocybin was prevented by intra-left nucleus accumbens injection of 0.3 μg of the 5-HT2A receptor antagonist ketanserin. In rats that self-administered ethanol but not in those self-administering saccharin, dopamine D2 receptor (D2R) mRNA was increased in both the nucleus accumbens and the prefrontal cortex by psilocybin, while dopamine D1 receptor mRNA was increased only in the prefrontal cortex. As in humans, psilocybin reduced ethanol self-administration in rats through the 5-HT2A receptor within the left nucleus accumbens, possibly through increased D2R expression. Our results open unexpected perspectives regarding the hemispheric lateralization of psychedelic effects.
31
J E Leysen, C. J. E. Niemegeers, Jan M. Van Nueten et al. · Molecular Pharmacology · 1982 · 1.1K citations
Distinct functions of the two isoforms of dopamine D2 receptors
Alessandro Usiello, Ja‐Hyun Baik, Françoise Rougé‐Pont et al. · Nature · 2000 · 725 citations
Medicine, Neuroscience, Pharmacology +14
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Robin Carhart‐Harris, Leor Roseman, Mark Bolstridge et al. · Scientific Reports · 2017 · 588 citations · Full text
Medicine, Neuroscience, Psychiatry +17